BMS-919373 + Placebo (Matching with BMS-919373)
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Atrial Fibrillation
Conditions
Paroxysmal Atrial Fibrillation
Trial Timeline
Jul 25, 2014 → Jun 1, 2016
NCT ID
NCT02156076About BMS-919373 + Placebo (Matching with BMS-919373)
BMS-919373 + Placebo (Matching with BMS-919373) is a phase 2 stage product being developed by Bristol Myers Squibb for Paroxysmal Atrial Fibrillation. The current trial status is terminated. This product is registered under clinical trial identifier NCT02156076. Target conditions include Paroxysmal Atrial Fibrillation.
What happened to similar drugs?
0 of 20 similar drugs in Paroxysmal Atrial Fibrillation were approved
Approved (0) Terminated (4) Active (16)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02156076 | Phase 2 | Terminated |
Competing Products
20 competing products in Paroxysmal Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 36 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Ravulizumab | AstraZeneca | Pre-clinical | 30 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Danicopan | AstraZeneca | Phase 3 | 47 |
| LNP023 | Novartis | Pre-clinical | 33 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 40 |
| iptacopan | Novartis | Phase 2 | 35 |
| LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Pre-clinical | 30 |
| Iptacopan | Novartis | Phase 3 | 40 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 40 |
| LNP023 | Novartis | Phase 3 | 47 |
| LFG316 + LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Crovalimab | Roche | Phase 3 | 44 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 40 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 33 |
| Humanized anti-Factor Bb monoclonal antibody + Placebo | Sanofi | Phase 1 | 29 |